Trialbee and Castor Partner to Democratize Access and Simplify Enrollment to Clinical Trials Globally
Trialbee, the leading enrollment performance company, and Castor, a leading provider of decentralized and hybrid clinical trial solutions, today announced a strategic partnership to accelerate patient enrollment, optimize patient engagement, and reduce site burden for clinical trials globally.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210921005005/en/
Castor and Trialbee’s logical integration allows sponsors to meet enrollment timelines with continuous access to all their study data. Together, the fast-growing companies will expedite patient recruitment and streamline clinical trials through advanced data science and streamlined workflows for patient enrollment, data collection, and engagement. The partnership will diversify patient participation and improve equitable health outcomes for global decentralized and hybrid clinical programs.
“We are excited to partner with Trialbee to improve patient engagement, as well as optimize patient diversity and study inclusivity with real-time insights around patient demographics across all recruitment channels,” said Derk Arts, M.D., Ph.D., CEO & Founder, Castor. “Our partnership provides sponsors a seamless decentralized and hybrid clinical trial solution to manage all their clinical trial touchpoints and expand inclusivity at a global scale.”
Recruiting and retaining qualified clinical trial participants is increasingly difficult as clinical study designs become more complex. According to industry estimates, the amount of patient eligibility in clinical trials has increased approximately 150% in the last decade. As a result, life sciences companies demand a patient matching and enrollment platform that can help them better manage the patient’s journey into a clinical trial while optimizing enrollment outcomes. With Trialbee and Castor’s proven integrations, clinical trial sponsors can seamlessly manage all clinical trial touchpoints while ensuring data quality every step of the way.
“Over 70 percent of potential clinical trial participants live more than two hours away from a trial site, increasing the need for greater scale and reach in patient awareness for today’s trial designs,” said Matt Walz, Chief Executive Officer at Trialbee. “Through our combined capabilities, clinical trials can deploy an end-to-end solution to simplify the patient journey, including early introductions to clinical trials, enrollment performance analytics, and remote data capture for decentralized clinical trials.”
About Trialbee
Trialbee is the leading global data and technology platform for patient matching and enrollment in clinical trials. Trialbee Hive™ operationalizes real world data (RWD) and applies data science to match patients globally. Our enrollment platform simplifies the journey for matched patients to qualify and participate in clinical research. Partnering with Sponsors, CROs, and virtual/decentralized sites, and software providers, Trialbee is achieving patient enrollment goals and driving enhancements in diversity in clinical trial populations. We are the smartest way to match and enroll patients for your clinical trial. For more information, visit http://www.trialbee.com or contact us at solutions@trialbee.com.
About Castor
Castor is a leading provider of decentralized and hybrid clinical trial solutions to democratize research. With the highest-rated eClinical platform for decentralized and hybrid clinical trials, Castor’s plug-and-play platform offers rapid deployment at scale, enabling researchers to create a trial in a matter of clicks, with easy enrollment, consent, and real-world data capture. Castor is bringing human-centered design to the clinical trial process, from recruitment to analysis, and improving the quality, security, and reusability of data for researchers worldwide. For more information, visit www.castoredc.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210921005005/en/
Contact information
Doug Weatherhead
Castor
doug.weatherhead@castoredc.com
Media
Kimberly Ha
KKH Advisors
kimberly.ha@kkhadvisors.com
Rosina Ferrante
Gregory FCA (for Trialbee)
215-344-2113
rosina.ferrante@trialbee.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SPM International Launches SPM Academy Inc. – a New Global Center for ISO-Compliant Vibration Training and Certification3.11.2025 10:00:00 EET | Press release
SPM Instrument, a global leader in condition monitoring, is taking the next step in its mission to empower industries with knowledge and tools that ensure reliability and performance. SPM Academy Inc., based in the U.S., will serve as a worldwide hub for vibration training and certification, strengthening industrial reliability expertise across sectors. Led by Bill Partipilo, CEO of SPM Instrument North America, the Academy builds on SPM’s long tradition of innovation and customer support through learning. “Our new global training center gives maintenance and reliability professionals the chance to develop their skills through interactive, high-quality course materials – in their local language, on a platform or location that suits them,” said Partipilo. SPM Academy combines practical exercises, simulators, and real-world case studies for a dynamic learning experience. Training and certification follow ISO/IEC 17024, ISO 18436-1, and ISO 18436-2. The SPM Academy Certification Center is
Kyowa Kirin International Announces Appointment of Julie Dehaene-Puype as President for the Region3.11.2025 10:00:00 EET | Press release
Kyowa Kirin International (“KKI”), a group company of Kyowa Kirin Co., Ltd. (TSE:4151, “Kyowa Kirin”), a Japan-based Global Specialty Pharmaceutical Company, today announced the appointment of Julie Dehaene-Puype as President for the Region, effective 1 November 2025. Julie follows the tenure of Jeremy Morgan, who has served as President for the International Region since 2023. Morgan will serve in an advisor role to the business through to the end of 2025, working in partnership with Dehaene-Puype to ensure a successful and smooth change for the company. “We are very pleased to welcome Julie to the company in the role as President of KKI,” said Tomohiro Sudo, Chief International Business Officer of Kyowa Kirin. “Julie joins us with extensive experience in global biotech and pharma spanning a 25-year career. I am confident that her expertise and her strong passion and care for people and patients will significantly contribute to KKI’s future growth for patients’ smiles, and we are look
Xpansiv Announces Acquisition of Evident to Strengthen Global Renewable Energy Markets3.11.2025 09:00:00 EET | Press release
Xpansiv® Limited (“Xpansiv”) and Evident Group Limited (“Evident”) today announced an agreement uniting their complementary registry and infrastructure capabilities to support the continued growth of the global renewable energy markets. The agreement, in which Xpansiv has wholly acquired Evident, follows an earlier, minority investment by Xpansiv in the registry operator and certification body. It combines Evident's international renewable energy for electricity “I-REC(E)” and other registries with Xpansiv’s North American Renewables Registry (NAR™) and Tradable Instrument for Global Renewables Registry (TIGR™) to establish a preeminent, global REC network with over 300 GW of capacity and more than 4,000 participating companies. “Today’s announcement reflects the shared goals and close relationship we have developed with Evident as we work to build energy transition solutions at scale, centering on transparent, independent certification and robust infrastructure,” said John Melby, CEO,
Merz Aesthetics ® Introduces New BELOTERO ® Syringe Offering Greater Precision, Comfort and Ease of Use3.11.2025 09:00:00 EET | Press release
Merz Aesthetics, the world’s largest dedicated medical aesthetics business, announced today the launch of a new syringe for its category-leading hyaluronic acid (HA) brand BELOTERO®*.The new syringe is ergonomically engineered to elevate the treatment experience, offering greater precision, comfort, and ease of use. The new syringe will launch first in Europe, and then will expand to markets worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251102677784/en/ “As the first region to introduce this innovation ahead of our global expansion, I’m proud to share this exciting milestone in BELOTERO®’s history as a trusted leader in hyaluronic acid treatments,” said Gonzalo Mibelli, President EMEA region. What is BELOTERO®? BELOTERO® is a thoughtfully designed, comprehensive range of highly cohesive hyaluronic acid fillers, developed to deliver predictable, harmonious results through seamless tissue integration. The full port
Newly Established Samsung Epis Holdings to Drive Growth for Samsung Bioepis and a New Subsidiary3.11.2025 04:17:00 EET | Press release
Samsung Epis Holdings Co., Ltd. today announced its establishment as a new investment holding company, following the spin-off of Samsung Bioepis Co., Ltd. from Samsung Biologics (KRX: 207940.KS). Samsung Epis Holdings will be listed on Korea Exchange (KRX) on November 24, 2025, after establishment of a new subsidiary company on November 14, 2025. Samsung Bioepis will continue to operate its biosimilar business as a 100% owned subsidiary of Samsung Epis Holdings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251030908044/en/ Kyung-Ah Kim will serve as the President and Chief Executive Officer (CEO) of Samsung Epis Holdings, in addition to her current role as the President and CEO of Samsung Bioepis. Kyung-Ah Kim will serve as the President and Chief Executive Officer (CEO) of Samsung Epis Holdings, in addition to her current role as the President and CEO of Samsung Bioepis. "The new investment holding company will focus on d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom